01—Abstract
Summary
Summary of the 10-Q filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation reported strong financial results for the first quarter of 2024, demonstrating robust top-line growth and improved profitability.
Net sales increased by 13.8% to $3.856 billiona compared to the prior year, driven by broad-based growth across its MedSurg and Cardiovascular segments, with notable strength in Cardiology and Peripheral Interventions. The company also showed significant improvement in net income, which more than doubled year-over-year, highlighting effective operational execution and expanding margins. The company continues to execute on its strategic priorities, including pending acquisitions.
The agreement to acquire Axonics, Inc. is progressing through regulatory review, with expected closure in the second half of 2024. Management expressed confidence in its liquidity and ability to fund operations, investments, and potential acquisitions, supported by a strong cash position and an undrawn revolving credit facility. Overall, the quarter's results indicate positive momentum and a solid foundation for future growth.
02—Key points
Key Highlights
- Net sales grew 13.8% year-over-year to $3.856 billion, exceeding the prior year's $3.389 billion.
- Net income attributable to common stockholders significantly increased to $495 million ($0.33 per diluted share) from $300 million ($0.21 per diluted share) in the prior year.
- Gross profit margin remained strong at 68.7%, slightly down from 69.3% in Q1 2023, but the company saw increased sales of higher-margin products.
- The pending acquisition of Axonics, Inc. is proceeding, with a projected closing in the second half of 2024, subject to regulatory approvals.
- Operating expenses increased in line with sales growth, with SG&A up 12% and R&D up 9%, reflecting investments in sales support and product pipeline.
- The company maintained a strong liquidity position with $2.329 billion in unrestricted cash and cash equivalents and no amounts outstanding under its $2.750 billion revolving credit facility.
- The effective tax rate decreased to 18.9% from 29.4% in the prior year, primarily due to acquisition expenses and discrete tax benefits.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Boston Scientific Corp kept $0.13.
- Revenue$3.86B100.0%
- Cost of revenue−$1.21B31.3%
- Gross profit$2.65B68.7%
- Operating costs−$1.97B51.2%
- Operating income$675.0M17.5%
- Interest, other & tax−$180.0M4.7%
- Net income$495.0M12.8%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 1, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $3.86B$3.39B | +13.8% |
| Cost of Revenue | $1.21B$1.04B | +16.3% |
| Gross Profit | $2.65B$2.35B | +12.7% |
| SG&A Expenses | $1.36B$1.22B | +12.3% |
| Operating Expenses | $1.97B$1.80B | +9.8% |
| Operating Income | $675.00M$552.00M | +22.3% |
| Interest Expense | $69.00M$65.00M | +6.2% |
| Net Income | $495.00M$314.00M | +57.6% |
| EPS (Basic) | $0.34$0.21 | +61.9% |
| EPS (Diluted) | $0.33$0.21 | +57.1% |
| Shares Outstanding (Basic) | 1.47B1.44B | +2.3% |
| Shares Outstanding (Diluted) | 1.48B1.45B | +2.5% |
05—Questions
Frequently Asked Questions
What were the key drivers of Boston Scientific's revenue growth in Q1 2024?
Revenue growth was primarily driven by strong performance across both the MedSurg and Cardiovascular segments. Key contributors included the Cardiology business, particularly the WATCHMAN FLX™ LAAC Device and electrophysiology products, and the Peripheral Interventions business, boosted by its interventional oncology and drug-eluting portfolios. Broader market expansion and strategic acquisitions also played a role.
How is the pending acquisition of Axonics progressing, and what is the expected timeline for closing?
Boston Scientific announced its definitive agreement to acquire Axonics, Inc. in January 2024. Both companies have received a 'Second Request' from the FTC, which extends the regulatory review period. The company expects the transaction to be completed in the second half of 2024, contingent upon the satisfaction of customary closing conditions and regulatory approval.
What is the company's liquidity position and outlook?
Boston Scientific maintains a strong liquidity position, reporting $2.329 billion in unrestricted cash and cash equivalents as of March 31, 2024. Additionally, the company has a $2.750 billion revolving credit facility, of which no amounts were outstanding. Management believes these resources, combined with expected cash flow from operations, are sufficient to fund operations, investments, and debt obligations for the foreseeable future.
What factors contributed to the change in the company's effective tax rate?
The effective tax rate decreased to 18.9% in Q1 2024 from 29.4% in Q1 2023. This reduction was primarily due to certain charges related to acquisition expenses and discrete tax benefits, including those related to unrecognized tax benefits and stock-based compensation. The prior year's rate was impacted by discrete charges for provision-to-return adjustments.
06—Continue